Dreyling M H, Schrader K, Fonatsch C, Schlegelberger B, Haase D, Schoch C, Ludwig W, Löffler H, Büchner T, Wörmann B, Hiddemann W, Bohlander S K
Department of Hematology/Oncology, University of Göttingen, Göttingen, Germany.
Blood. 1998 Jun 15;91(12):4662-7.
The translocation t(10;11)(p13;q14) has been observed in acute lymphoblastic leukemia (ALL) as well as acute myeloid leukemia (AML). A recent study showed a MLL/AF10 fusion in all cases of AML with t(10;11) and various breakpoints on chromosome 11 ranging from q13 to q23. We recently cloned CALM (Clathrin Assembly Lymphoid Myeloid leukemia gene), the fusion partner of AF10 at 11q14 in the monocytic cell line U937. To further define the role of these genes in acute leukemias, 10 cases (9 AML and 1 ALL) with cytogenetically proven t(10;11)(p12-14;q13-21) and well-characterized morphology, immunophenotype, and clinical course were analyzed. Interphase fluorescence in situ hybridization (FISH) was performed with 2 YACs flanking the CALM region, a YAC contig of the MLL region, and a YAC spanning the AF10 breakpoint. Rearrangement of at least one of these genes was detected in all cases with balanced t(10;11). In 4 cases, including 3 AML with immature morphology (1 AML-M0 and 2 AML-M1) and 1 ALL, the signals of the CALM YACS were separated in interphase cells, indicating a translocation breakpoint within the CALM region. MLL was rearranged in 3 AML with myelomonocytic differentiation (2 AML-M2 and 1 AML-M5), including 1 secondary AML. In all 3 cases, a characteristic immunophenotype was identified (CD4+, CD13-, CD33+, CD65s+). AF-10 was involved in 5 of 6 evaluable cases, including 1 case without detectable CALM or MLL rearrangement. In 2 complex translocations, none of the three genes was rearranged. All cases had a remarkably poor prognosis, with a mean survival of 9.6 +/- 6.6 months. For the 7 AML cases that were uniformly treated according to the AMLCG86/92 protocols, disease-free and overall survival was significantly worse than for the overall study group (P = .03 and P = .01, respectively). We conclude that the t(10;11)(p13;q14) indicates CALM and MLL rearrangements in morphologically distinct subsets of acute leukemia and may be associated with a poor prognosis.
在急性淋巴细胞白血病(ALL)以及急性髓细胞白血病(AML)中均观察到了t(10;11)(p13;q14)易位。最近一项研究显示,所有伴有t(10;11)的AML病例中均存在MLL/AF10融合,且11号染色体上存在从q13至q23的各种断点。我们最近在单核细胞系U937中克隆了CALM(网格蛋白组装淋巴细胞髓细胞白血病基因),它是位于11q14的AF10的融合伴侣。为了进一步明确这些基因在急性白血病中的作用,我们分析了10例经细胞遗传学证实为t(10;11)(p12 - 14;q13 - 21)且具有明确形态学、免疫表型和临床病程的病例(9例AML和1例ALL)。使用位于CALM区域两侧的2个YAC、MLL区域的YAC重叠群以及跨越AF10断点的YAC进行间期荧光原位杂交(FISH)。在所有具有平衡t(10;11)的病例中均检测到至少其中一个基因发生重排。在4例病例中,包括3例形态不成熟的AML(1例AML - M0和2例AML - M1)和1例ALL,CALM YAC的信号在间期细胞中分离,表明CALM区域内存在易位断点。3例具有粒单核细胞分化的AML(2例AML - M2和1例AML - M5,包括1例继发性AML)中MLL发生重排。在所有这3例病例中,均鉴定出一种特征性免疫表型(CD4 +、CD13 -、CD33 +、CD65s +)。在6例可评估病例中的5例中AF - 10受累,包括1例未检测到CALM或MLL重排的病例。在2例复杂易位中,这三个基因均未发生重排。所有病例预后均明显较差,平均生存期为9.6±6.6个月。对于按照AMLCG86/92方案统一治疗的7例AML病例,其无病生存期和总生存期均显著差于整个研究组(分别为P = 0.03和P = 0.01)。我们得出结论,t(10;11)(p13;q14)表明在形态学不同的急性白血病亚组中存在CALM和MLL重排,并且可能与预后不良相关。